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Introduction
Reconstruction of skeletal defects and limb lengthening
by distraction osteogenesis is a master technique
providing solution to many complex orthopaedic
problems. Woven bone formed initially between the
distracted ends later consolidates into mature bone.
Consolidation time is usually three times longer than the
distraction time or sometimes even longer. This may
require the patient to wear the external fixator for long
duration, sometimes even up to a year. A prolonged
fixator time may produce non-compliance to this
treatment method and predisposes to pin tract infection
and wire loosening. Efforts to minimise consolidation
time represent an active area of interest for research. Both
pharmacological and mechanical solutions are being
studied.
Teriparatide is the synthetic form of naturally occurring
human parathyroid hormone (PTH), amino acid sequence
1 through 34, of the complete molecule (containing 84
amino acids). It is a medication to treat osteoporosis and
works in a different way than other drugs for
osteoporosis. Teriparatide causes new bone formation
and has been approved by US Food and Drug
Administration (FDA) to treat osteoporosis in
postmenopausal women and in men with hypogonadal
or idiopathic osteoporosis who are at high risk for
fracture. Teriparatide has been shown to increase the
density and mechanical strength of the callus after
fracture healing in experimental models.1,2
To date, only few studies have addressed the role of
teriparatide in distraction osteogenesis. High doses of
60µg/kg and 25µg/kg have demonstrated to cause an
anabolic effect on new bone formation.3,4 The role of
teriparatide in a low dose on bone formation in
distraction osteogenesis has not been observed
previously. The current study was planned to see the
effects of a much lower dose of teriparatide (10 µg/kg) to
investigate its role in new bone formation in a rat model
of distraction osteogenesis.
Subjects and Methods
The experimental study was conducted at the Aga
Khan University Hospital (AKUH), Karachi, in
November-December 2010, and comprised male
Sprague-Dawley rats weighing 250gm each. The rats
were obtained from the institutional animal breeding
facility and housed in cages containing 3 rats each.
They were fed standard rat chow and water ad libitum.
The animal rooms had a 12-hour light-dark cycle, and
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Abstract
Objective: To determine the effect of teriparatide on new bone formation in a rat model of distraction osteogenesis. 
Methods: The experimental study was conducted at the Aga Khan University Hospital, Karachi, in November-
December 2010, and comprised male Sprague-Dawley rats weighing 250gm each who were allocated to two
treatment groups, teriparatide and saline, both given subcutaneously for 7 weeks. Femoral distraction was done for
3 weeks at the rate of 0.4mm/day, followed by a further 4 weeks for consolidation. New bone formation was assessed
using X-ray scoring system, bone densitometry and histology.
Results: The 12 rats in the study were divided into two groups of 6(50%) each. All rats in the teriparatide group
showed new bone formation whereas bone formation was present only in 2(33.3%) rats in the saline group. Bone
densitometry showed that area (size) of the new bone formed adjacent to the margins of the osteotomy site as well
as the total bone mineral content of the new bone was significantly higher (p<0.05) in the teriparatide group.
Histological analysis showed larger but statistically insignificant (p>0.05) area of woven and trabecular new bone in
the teriparatide group. 
Conclusion: The results suggested a promising role of parathyroid analogue therapy in distraction osteogenesis for
promoting bone formation and consolidation. This may have strong clinical implications in cases of limb
lengthening and bone transport.
Keywords: Teriparatide, Parathyroid hormone, Distraction osteogenesis, Limb lengthening, Bone formation,
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controlled temperature and humidity. 
Uniplanar external fixators with threaded rods for
distraction, drill, drill guide (jig) and fixator pins were
obtained from Karolinska University Hospital, Stockholm,
Sweden. 
All experiments were performed in accordance with
international guidelines for the care and use of
experimental animals, and after approval from the
institutional ethics committee. Rats were anaesthetised
using intraperitoneal injection of a combination of
pentobarbital (500mg/10ml), ketamine (1: 1.333;
Gedeon Richter) and valium (10mg/2ml, 1:10; Roche)
after short exposure to ether in a glass jar. Skin of the
lower abdomen and right lower limb was shaved,
scrubbed with Hibiscrub™ and painted with Pyodine™.
After sterile draping, incision was made over the right
femur. Vastus lateralis muscle was reflected from lateral
inter-muscular septum anteriorly to expose shaft of the
femur.  Using drill guide, four holes were drilled through
lateral cortex, and Schanz screws were placed. The
Schanz screw ends were passed through stab incisions
on the skin and attached to the external fixator. Mid-
shaft corticotomy was performed using multiple drill
holes and a curved hand-saw. Using the fixator's
threaded rod mechanism, both bone ends were brought
in close apposition. The vastus muscle was replaced over
the bone, anchored to the septum with 4/0 vicryl, and
skin was sutured with 4/0 silk (Figure-1A).
Postoperatively, all animals were given antibiotic
Cefazolin (Inj. Kefzol, 100mg/kg, AGP Pharma) twice a
day and analgesia with Paracetamol (60mg/kg, Glaxo
Smith Kline) and Ibuprofen (80mg/kg, Abbot) mixed in
drinking water for the first three days. Rats were allowed
full activity within their cages (Figure-1B). After a latent
period of 7 days, distraction was started at 0.4mm a day
(0.2mm twice a day), and continued for 3 weeks. A
further 4 weeks were given for consolidation of the
regenerated bone; rats were then euthanised with
ketamine overdose and both lower limbs were
dissected.
Rats were allocated to two treatment groups, teriparatide
and saline. Teriparatide was obtained in the form of pre-
filled pens (Forteo™; Eli lilly Pakistan Pvt ltd)). Drug was
diluted in 720µl sterile water to a concentration of
20µg/ml, and administered thrice a week by
subcutaneous injection at a dose of 10µg/kg body
weight5 per dose for 7 weeks.
Samples were kept in 4% Zamboni's fixative for 24 hours,
and then demineralised in 20% ethylenediaminetetraacetic
acid (EDTA) (pH 7.3).6
X-rays were performed at 3 time points; immediately after
surgery, at the end of distraction, and at the end of
another 4 weeks of consolidation phase. X-rays were
scored for the quality of regenerated bone according to
the method of Lane and Sandhu.7 Three blinded
observers performed scoring of scanned X-ray images
independently, and the mean was used for statistical
comparisons using Mann-Whitney test.
Bone densitometry (DEXA) scan was performed after the
limbs were dissected. The corticotomy gap was analysed
for bone mineral content, density and new bone area.
Separate analysis was performed at centre of bone
regenerate and at two ends adjacent to the original bone
ends. The data obtained included ossified area (cm2),
bone mineral content (mg) and bone mineral density
(mg/cm2). Data was described as mean ± standard
deviation (SD), and group comparisons were made using
student's t-test. Histological analysis entailed image
analysis of area fraction per high power field (HPF) for
intramembranous ossification, enchondral ossification,
woven bone and mature trabecular bone. A Nikon
light/fluorescence microscope (Eclipse E800; Nikon Inc,
Yokohama, Japan) with a 20X objective and a DXM-1200
digital camera with the supplied ACT-1 software was
used. Digital image analysis was performed using Image
Tools public domain software (Version 3.0, University of
Texas, San Antonio, USA). The observer demarcated on
computer the areas on each image according to the
above four tissue types, and the area was measured in
square microns. The whole tissue sections were analysed,
and mean area per HPF was calculated. Area fraction for
each tissue type was then calculated. Data was described
as mean ± standard error of mean (SEM), and group
comparisons were made using Mann-Whitney non-
parametric test. 
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Figure1 (A,B): Photographs showing (A) application of the external fixator with two
pins proximal and two pins distal to the femoral osteotomy just before skin closure, and
(B) rat with full weight bearing on the operated leg.
Results
The 12 rats in the study were divided into two groups of
6(50%) each. All rats in the teriparatide group showed
new bone formation whereas bone formation was
present only in 2(33.3%) rats in the saline group. All rats
started ambulation after recovery from anaesthesia, and
exhibited full weight bearing within 1-2 days (Figure-1B).
In 2(33.3%) rats in the saline group, new bone formation
was observed, while in all the 6(100%) rats in teriparatide
group there was new bone formation Figure-2). Mean
radiological score was 2.2±0.5 for the saline group
compared to 3.2±0.3 for teriparatide group, but the
difference was not statistically significant (p>0.05).
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Figure 5: Chart showing results of histological analysis. The teriparatide group has
higher mean area fraction for woven bone and lower intramembranous ossification as
compared to the saline group, but the difference was not statistically significant.
Figure 3: Charts showing results of bone mineral analysis of the regenerate bone region in control and teriparatide groups. The bone area as well as mineral content of the opposite
ends, i.e. the peripheral regions of the distraction region, were significantly higher in teriparatide compared to saline group. *p<0.05, ** p<0.01. 
Figure 4(A,B): Photomicrograph of a sample of regenerate tissue from a rat in the
control group (A) showing mesenchymal tissue [M] and some woven bone [W] amidst
large lacunar spaces [L], and from the teriparatide group showing intramembranous
[M] and enchondral [E] ossification, woven bone [W] and inflammatory infiltrate [I].
Figure 2 (A-F): Radiographs showing the femur after osteotomy (A,D), at completion
of distraction (B,E) and consolidation (C,F) belonging to control (A-C) and teriparatide
(D-F) groups.
The average area (size) of new bone formed adjacent to
margins of the osteotomy site was 28% greater in the
teriparatide group compared to the saline group
(p=0.025) (Figure-3). Moreover, the average mineral
content of the same area was 88% higher in the
teriparatide group (p=0.007). DEXA was also 48% higher
in the teriparatide group (p=0.076).
On histological analysis of the area fraction among the
different tissue types, the teriparatide group exhibited a
greater proportion of woven bone (+47%) and lesser of
intra-membranous ossification (-38%) (p>0.05).  When
comparing the total area (µ2/HPF), the teriparatide
group appeared to have larger area of woven bone
(+153%) and trabecular new bone (+225%) (p>0.05)
(Figures-4,5).
Discussion
This pilot study shows that treatment with parathyroid
hormone analogue teriparatide at a dose of 10µg/kg
thrice weekly results in significant increase in size of new
bone formation and total mineral content in rat model of
distraction osteogenesis. Our results confirm the known
anabolic effects of teriparatide therapy on new bone
formation in distraction osteogenesis. 
To our knowledge only few experimental studies have
investigated the effects of teriparatide on bone
regeneration in distraction osteogenesis.3,4 The studies
used much higher doses of 60µg/kg and 25µg/kg
respectively. We tested a much smaller dose (10µg/kg),
which also showed beneficial effect of teriparatide in
distraction osteogenesis. This dose is closer to the human
dose of 0.3µg/kg/day. One study5 showed that
teriparatide at a dose of 10ug/kg administered to rats with
fractured femora resulted in increased bone mineral
density (BMD) compared to vehicle treated controls. We
think that using low-dose teriparatide is cost-effective,
ensures better patient compliance and reduces
undesirable side effects etc.
A study3 showed that the total regenerate callus volume
was 58% higher and the bone mineral content (BMC)
and BMD were 24% higher in teriparatide-treated rats
than in controls.  Another study4 on rabbits showed a 60
% higher BMC in teriparatide-treated group than in
controls. Our study showed that average area (volume)
of new bone formed adjacent to the margins of the
osteotomy site was 28% greater in the teriparatide
group compared to the saline group. The average BMC
of the same area was 88% higher in the teriparatide
group (p<0.01 ) and BMD was  48% higher in the
teriparatide group, though not significant. Our results
are quite comparable to the other two studies despite
using a much lower dosage schedule.  In addition, our
findings confirm the results of other studies showing
anabolic effects on newly forming bone in fracture
healing, bone chamber studies, or titanium implant
anchorage in low-density trabecular bone.1,2,8-10 The
anabolic effect of teriparatide is also visible on the intact
contralateral tibia as was shown in one study.3 We did
not check this outcome parameter.
One study11 suggested that bone formation in the
distracted gap was most active between 18 and 24 days
after the operation. It suggested that interventions to
enhance bone formation should focus on this time period.
Osteoblasts are the target cells for teriparatide; their
presence in the immature tissue containing pluripotent
cells during distraction phase is not known. A study4
showed that giving teriparatide during both distraction
and consolidation phases is not superior to giving it
during consolidation phase only. Giving the drug
throughout the treatment period may not be very cost-
effective. As such, the effect of low-dose teriparatide in
different phases of distraction and consolidation needs to
be studied further. 
Conclusion
The results suggest a positive role of teriparatide on
new bone formation during distraction and
consolidation phases; a similar anabolic response can
be expected in humans undergoing distraction
osteogenesis. There is sufficient evidence to warrant
clinical studies on the possible utility of teriparatide for
improving bone regenerate formation in distraction
osteogenesis. Trials may employ low doses, which are
likely to cause fewer untoward effects and result in
better patient compliance in addition to being more
cost-effective than the doses conventionally used for
osteoporosis.
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